Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592368 | 0.88 | ATM (0.44) | TDP1ATMMAPTALDH1A1GABRA1 | |
| SCHEMBL9747677 | 0.84 | EGFR (0.43) | TDP1MAPTSIRT6ALDH1A1DTYMK | |
| SCHEMBL557153 | 0.84 | VCAM1 (0.46) | TDP1ATMMAPTSIRT6ALDH1A1 | |
| SCHEMBL31548078 | 0.83 | SIRT6 (0.56) | TDP1ATMSMN1; SMN2MAPTSIRT6 | |
| SCHEMBL137523 | 0.83 | SIRT6 (0.56) | TDP1ATMSMN1; SMN2MAPTSIRT6 | |
| SCHEMBL8767674 | 0.82 | TDP1 (0.47) | TDP1MAPTSIRT6ALDH1A1DTYMK | |
| SCHEMBL30032292 | 0.82 | MAPT (0.41) | TDP1SMN1; SMN2MAPTSIRT6ALDH1A1 | |
| SCHEMBL1186362 | 0.82 | TDP1 (0.52) | TDP1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL27834938 | 0.81 | ATM (0.41) | TDP1ATMSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL19782588 | 0.81 | TDP1 (0.48) | TDP1SMN1; SMN2MAPTSIRT6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373626-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-24 | — | — | EP | disclosed |
| US-8354399-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-15 | — | — | US | disclosed |
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| EP-2274280-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | Biolipox AB (SE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | TDP1 4176/4885ATM 4529/4885SMN1; SMN2 4779/4885 |
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | TDP1 1928/4885ATM 226/4885SMN1; SMN2 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.